Full article view2017-09-21T08:01:31+00:00
Back to News & Insights »

Precision for Medicine Raises $150 Million to Fund Growth and Expansion

(Bethesda, MD) April 2, 2013 – Precision for Medicine, Inc., formed in 2012 to support next-generation approaches to drug development and commercialization, today announced that it has secured $150 million in private equity financing to support acquisitions and development. Precision for Medicine is building a comprehensive platform of specialized development and commercialization services to support life science companies that are seeking to capitalize on the benefits of patient-centered, precision medicine. Oak Investment Partners, J.H. Whitney and Company, and LCI Capital led the financing.

Ethan D. Leder and Mark P. Clein, co-founders of the Maryland-based company, said the funding will be used to acquire the expertise and infrastructure necessary to guide innovative medical products from discovery to patients.

“Next-generation medicine is about placing greater emphasis on the patient as the focal point of all product development activity,” says Ethan Leder, CEO and co-founder. “Life science companies that are moving to embrace precision medicine will fundamentally improve the efficiency of drug development and will deliver products that offer better results for patients. Our mission is to build the services and infrastructure to support life science innovators as they develop new products that deliver the best outcomes to patients.”

“This financing will allow us to aggressively acquire and grow a unique portfolio of capabilities designed to deliver lower development costs, speed the time to market, and improve success rates,” said Mark P. Clein, President and co-founder.

Precision for Medicine’s growing team of over 130 employees includes recognized experts in regulatory sciences, clinical development, commercialization, and product strategy. Precision’s experts collaborate with clients to speed approval, reduce costs, and optimize market launch through solutions that combine innovative approaches to patient selection with a deep understanding of payers, regulators, science, and policy.

Precision also provides next generation bioservices solutions including bio-repository, sample management, and cellular products from its state-of-the-art bio-repository facilities in Frederick and Gaithersburg, Maryland, managing more than 15 million samples. The Precision Bioservices team has a distinguished reputation and many long-term relationships with life science and academic research institutions, including the US Government’s National Institutes of Health.

About Precision for Medicine
Precision for Medicine is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. The company is headquartered in Bethesda, MD.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK